

DIPODERM PLUS

Cream ,Ointment

Betamethasone (dipropionate) + Gentamicin (as sulfate)



Composition:

1 g of cream or ointment contains:

Betamethasone dipropionate 0.64 mg Equivalent to 0.5 mg Betamethasone, Gentamicin (as sulfate) 1 mg.

Excipients:

Dipoderm plus cream :chloroacresol, cetostearyl alcohol, sodium phosphate monobasic, phosphoric acid,white petrolatum,mineral oil ,poly ethylene glycol 1000 monocetyl ether,sodium hydroxide or phosphoric acid for PH adjustment,purified water.

Dipoderm plus ointment: mineral oil,white petrolatum .

Mechanism of action:

This product combines the antibacterial action of gentamicin (an aminoglycoside antibiotic) with the anti-inflammatory, antipruritic and vasoconstrictive properties of betamethasone dipropionate (a highly potent, class III corticosteroid).

Gentamicin interferes with the growth of sensitive bacteria by inhibiting protein synthesis. Its action against pathogenic, Gram-negative and Gram-positive bacteria is bactericidal, and is based on the ability of the antibiotic to bind to bacterial 30S ribosomal subunits.

susceptible bacteria to gentamicin:

Streptococcus, coagulase negative, enterobacter sp., *serrata*, *klebsiella* sp.,*proteus* mirabilis, *Escherichia coli*,*pseudomonas aeruginosa*, *Staphylococcus*,*proteus* (indole –positive).

Bacteria most resistant to aminoglycosides:

meningococci, *Streptococcus pneumoniae*, most types of streptococci (notably Group D).

Mycoplasma sp., *Chlamydia* sp and anaerobes such as *Bacteroides* sp. and *Clostridium* sp.

Inflamed skin diseases due to secondary bacterial infections can be treated with this product, bringing relief from subjective complaints such as pruritus.

The ointment is particularly suitable for use on dry and chapped skin.

The cream is a cooling, non-oily, water-permeable oil-in-water emulsion, which is indicated for acute and weeping stages of disease.

Pharmacokinetics:

No penetration or absorption studies have been performed on this galenic formulation. Under normal circumstances, only a fraction of the locally applied amount of corticosteroid is systemically available. Penetration and permeation rates depend on the body site, skin condition, the galenic formulation being used, patient age and method of application.

Gentamicin absorption need hardly be considered when used on intact skin. However, increased percutaneous absorption should be taken into account in cases of keratin layer loss, inflammation and occlusive/ extensive application. When used topically, absorption may be greater with the cream formulation when compared with the ointment.

Indications:

Cream is indicated for the relief of the inflammatory manifestations of corticosteroid responsive dermatoses when complicated by secondary infections caused by organisms susceptible to gentamycin.

Ointment is indicated for topical treatment of dermatosis complicated by secondary infection caused by organisms sensitive to Gentamicin.

Posology and method of administration:

Adolescents and Adults:

Apply a thin film to the affected skin areas twice daily and carefully rub in. Frequency of application should be determined by the physician according to the severity of the condition.

For some patients, adequate maintenance therapy may be achieved with less frequent application. Duration of therapy varies depending upon the extent and location of disease and patient response. However, if clinical improvement is not achieved by two to three weeks, diagnosis should be reviewed.

Children 2 to 12 years old:

Apply a thin film to only the affected skin and carefully rub in. Apply a sufficient amount no more frequently than twice daily at least 6-12 hours between applications. Application to face, neck, scalp, genitalia, rectal area, and skin flexures should be applied under medical supervision. Limit treatment to no more than 5 to 7 days.

Contraindications:

Hypersensitivity to the active substances or to any of the excipients used in the preparation as well as to aminoglycoside antibiotics (cross allergy to gentamicin).

Skin infections [viral, bacterial (incl. TB) and fungal aetiology], vaccine reactions, skin ulcers and acne are contraindicated in the case of locally applied corticosteroids. Facial application is not recommended in the presence of rosacea or perioral dermatitis.

This product should not be applied to mucous membranes, to the eyes or the area surrounding the eyes.

warning and precautions :

If irritation or sensitization develops with the use of this product. Cream or Ointment, treatment should be discontinued and appropriate therapy instituted.

When applied topically, systemic absorption of the active substances may be increased if this product is used extensively, particularly during prolonged use or if applied to damaged skin or when using beneath occlusive dressings, particular caution is recommended in paediatric use.

During concomitant systemic administration of aminoglycoside antibiotics, it should be remembered that, in cases of increased dermal absorption, a cumulative toxic effect (ototoxicity, nephrotoxicity) is possible.

During long-term treatment with preparations containing antibiotics, non-susceptible microorganisms may develop, in particular mycosis. In such an event, or at the onset of a superinfection, appropriate treatment should be instituted.

High-dose, extensive or occlusive application of potent or highly-potent corticosteroids should only take place under regular, medical supervision; particularly in regard to the suppression of endogenous corticosteroid production and a possible metabolic effect.

A period of 2-3 weeks' continuous treatment should preferably not be exceeded.

Highly-potent, potent and medium-dose corticosteroids should be used with caution in the facial and genital region; treatment should not exceed one week in such cases. Generally speaking, only low-dose corticosteroids should be used around the eyes (glaucoma). Corticosteroids may mask the symptoms of an allergic skin reaction to one of the product ingredients.

The patient should be instructed to use the product solely in the treatment of his/her current skin condition, and not to pass it on to others.

Use in pediatric patients:

Use of this product in paediatric patients younger than 2 years of age is not recommended. When compared with adults, paediatric patients may demonstrate greater susceptibility to hypothalamic-pituitary-adrenal (HPA) axis suppression (induced by topical corticosteroids) and to exogenous corticosteroid effects, as absorption in children is greater due to the higher skin surface area to body weight ratio. HPA axis suppression, Cushing's syndrome, linear growth retardation, delayed weight gain and intracranial hypertension have been reported in children receiving topical corticosteroids.

Symptoms of adrenal suppression in children include low plasma cortisol levels and absence of response to ACTH stimulation. Symptoms of intracranial hypertension include bulging fontanelles, headache and bilateral papilledema.

Interactions:

When this product is used in the genital or anal region, the presence of petroleum jelly and liquid paraffin (excipients used in the product) may diminish the tear resistance of concomitantly used latex condoms, thereby compromising their safety when in use.

Precautions:

In animal studies, topical application of corticosteroids was shown to have a teratogenic effect. There are no data on its use in human pregnancies.

Aminoglycosides cross the placental barrier and may harm the foetus if administered to pregnant women. There have been reports of total, irreversible, bilateral, congenital deafness in infants whose mothers received aminoglycosides (including gentamicin) during pregnancy. During pregnancy, Diprogenta should only be used in cases where it is absolutely necessary.

Lactation:

It is not known whether topically applied corticosteroids pass into breast milk. However, systematically available corticosteroids are excreted in breast milk.

It is not known whether gentamicin passes into breast milk. This product may not be used by nursing mothers.

Undesirable effects:

Initiation of treatment:

Skin:

Rare: irritations, burning sensations, pruritis, skin dryness, hypersensitivity reactions to one of the ingredients used in the product and skin, discoloration.

Extensive, occlusive and/or prolonged use:

During extensive, occlusive and/or prolonged use, local skin changes may occur. During extensive use, systemic effects (adrenal suppression) may occur.

It should be remembered that patients are at greater risk of developing secondary infections as a result of diminished local resistance to infection.

Skin:

Localized skin changes such as atrophy (particularly facial), striae, distensae, cutaneous bleeding, purpura, steroid acne, rosacea-like/ perioral dermatitis and hypertrichosis, skin discoloration. It is not known whether the skin discoloration is reversible.

Uncommon: contact sensitisation to gentamicin.

Rare: skin irritation (erythema, pruritis). Possible photosensitisation was observed in some patients; however, it was impossible to reproduce this effect when gentamicin was reapplied, with subsequent exposure to UV radiation.

Endocrine system:

Endogenous corticosteroid synthesis suppression; overactive adrenal glands with oedema.

Metabolism:

Manifestation of latent diabetes mellitus.

Ear, inner ear/ renal:

In cases of concomitant systemic administration of aminoglycoside antibiotics, cumulative ototoxicity/ nephrotoxicity is possible if this product is used extensively or on damaged skin.

Musculoskeletal system:

Osteoporosis, growth retardation (in children).

Osteoporosis:

Symptoms: Excessive or prolonged use of topical corticosteroids may lead to a suppression of the pituitary-adrenal function, and may cause secondary adrenal insufficiency and symptoms of adrenal cortex hyperactivity, including Cushing's syndrome.

It cannot be excluded that a single excessive dose of gentamicin might induce such symptoms.

Treatment: Appropriate symptomatic treatment is indicated. Acute symptoms of adrenal cortex hyperactivity are usually reversible. Electrolyte imbalances should be treated where required. In cases of chronic toxicity, withdrawal of corticosteroids should be gradual.

If overgrowth by non-susceptible organisms occurs, stop treatment with Diprogenta Cream or Ointment and institute appropriate antimycotic or antibacterial treatment.

Storage conditions:

store at temperature below 25°C

Presentation : Aluminium tube contains 20 g Dipoderm plus cream.

Aluminium tube contains 20 g Dipoderm plus ointment

* THIS IS A MEDICAMENT *

- Keep out of reach of children.
- A medicament is a product which affects your health, and its consumption contrary to instructions is dangerous for you.
- Follow strictly doctor's instructions, the method of use and instructions of this product when using the medicament.
- The doctor and pharmacist are experts in medicine, its benefits and risks.
- Do not by yourself interrupt the period of treatment prescribed for you.
- Do not repeat the same prescription without consulting your doctor.

(Union of Arab Pharmacists)



Mediotic Labs Pharmaceutical Industries

www.mediolic.com - Homs - SYRIA - Tel: 2222160